Pricing Sign in

ACTU

Actuate Therapeutics Inc.distress 8/10 · high distress / dilution risk

$1.27+1%today-85% from 52w high

actuatetherapeutics.com12 employeesFounded 2015Fort Worth, TXBiotechnology

Oncology 2

Lead: Refractory Cancer · target GSK-3β

Revenue

pre-revenue

Liquidity

$8M

Runway

0.4 yrs

Shares 1y

+15%

Price & events

-76.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.8%

1D

-23.2%

1W

-33.9%

1M

-49.6%

3M

-76.0%

6M

-80.7%

1Y

—

2Y

—

5Y

-85.2%

All

Overview

Market Cap: $30.51M
Volume: 16.39K
52 Week Range: $1.21 – $8.72
Total Shares: 23.93M
Float Shares: 8.57M
Short %: 6.56%
% Held by Insiders: 14.84%
% Held by Institutions: 58.20%
RVOL: 0.04x

Pipeline stages · 1 programs

9-ING-41, Gemcitabine - 21 day cycle, DoxorubicinGSK-3β

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 2 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-06	Phase 2	9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin	Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma	350	active not recruiting
2025-07-07	Phase 1	9-ING-41, Irinotecan, Temozolomide	Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma	40	terminated

Catalyst news & presentations · 7

second half of 2026Guided 55%trial initiationsecondaryPhase 1/2elraglusib · Phase 1/2 study of oral elraglusib to evaluate safety, PK, and efficacy.SEC 8-K
2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
mid-2026conferencedata presentationsecondaryelraglusib · Preclinical results for elraglusib plus RAS inhibitor combination.SEC 8-K
2026-05-11fda agreementelraglusib · FDA cleared IND application for oral elraglusib Phase 1/2 study.SEC 8-K
January 9, 2026conferencedata presentationsecondaryPhase 2elraglusib · Oral and poster presentations of Phase 2 trial results at ASCO GI 2026.SEC 8-K
2H 2025readoutPhase 1elraglusib · Topline Phase 1 data from ongoing Phase 1/2 trial in relapsed/refractory Ewing sarcomaSEC 8-K
1H 2025readoutPhase 2elraglusib · Topline data from ongoing randomized Phase 2 trial (Actuate-1801 Part 3B)SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 23,925,852 · 4 offerings/1y · 0 PIPEs

2025-11-288-Kmaterial_agreement
2025-11-28424B5offering
2025-09-108-Kmaterial_agreement
2025-09-10424B5offering
2025-09-09424B5offering
2025-09-08EFFECTshelf_effective
2025-09-02S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

no consensus

2026-05-18HC Wainwright & Co.Buy
2026-04-22HC Wainwright & Co.Buy
2026-04-13HC Wainwright & Co.Buy
2025-11-19HC Wainwright & Co.Buy
2025-09-23HC Wainwright & Co.Buy
2025-08-26B. Riley SecuritiesBuy

Competitors — GSK-3β

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.